Physicians who work in the intensive care unit (ICU) almost certainly will transfuse blood components to many patients. All transfusing physicians should have an understanding of the blood donation process and the products that are made from the donation. Risk of transfusion-transmitted viruses is often uppermost in the minds of patients and their families. This chapter reviews the most important aspects of blood product transfusion in critically ill patients.
KeywordsSickle Cell Disease Platelet Concentrate Acute Chest Syndrome Apheresis Platelet Canadian Critical Care Trial Group
Unable to display preview. Download preview PDF.
- Litty C. A review: Transfusion reactions. Immunohematology 1996; 12: 72–79.Google Scholar
- Mintz PD (ed) Transfusion Therapy: Clinical Principles and Practice. Bethesda: American Association of Blood Banks, 1999.Google Scholar
- Mollison PL, Engelfriet CP, Contreras M (eds) Blood Transfusion in Clinical Medicine, 9th Ed. London: Blackwell, 1993.Google Scholar
- Rossi EC, Simon TL, Moss GS, Gould SA (eds) Principles of Transfusion Medicine, 2nd Ed. Philadelphia: Williams & Wilkins, 1996.Google Scholar
- Smith DM, Lipton KS. Leukocyte reduction for the prevention of transfusion-transmitted cytomegalovirus (TT-CMV). AABB Bulletin 97–2. Bethesda: American Association of Blood Banks, 1997.Google Scholar
- Vengelen-Tyler V (Ed). Technical Manual, 12th Ed. Bethesda: American Association of Blood Banks, 1996.Google Scholar